PAH News

Respiratory Procedure Eased Breathing in PAH, CTEPH Patients

Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest or with light activity may benefit from a procedure called respiratory rate modulation, a pilot, single-center study shows. The three-month procedure also led to lower symptom severity and decreased respiratory…

Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…

Study of Gene Activity in Endothelial Cells Aims to Better Treat PAH

Potential targets to treat pulmonary arterial hypertension (PAH) were identified by analyzing the gene activity of individual lung endothelial cells isolated from a mouse model of the disease. Study results were validated by cross-referencing them with rat and human gene activity datasets. “The identification of distinct molecular mechanisms and…

FDA Declines to Approve Tyvaso DPI, Citing Inspection Issue

Due to problems at a third-party facility, the U.S. Food and Drug Administration (FDA) has decided to not approve Tyvaso DPI, a dry powder inhaled formulation of treprostinil, at this time. According to United Therapeutics, the medication’s developer, the issue is expected to be dealt with soon. The company anticipates…

Potential Way of Treating PAH Seen in Blocking Specific MicroRNA

Blocking the activity of a small RNA molecule called microRNA-30a eased alterations in heart structure and blood vessel architecture in mouse models of pulmonary arterial hypertension (PAH), a new study reports. Results also showed that this molecule is present at abnormally high levels in PAH patients, supporting its potential…

Rare Inherited Mutations Shown to Cause Severe Childhood PAH

Rare mutations in the ATP13A3 gene caused a severe inherited form of childhood-onset pulmonary arterial hypertension (PAH), a case study of three families showed. These findings demonstrate the “growing importance” of genetic testing in patients with childhood-onset PAH, the scientists said, noting that the genetic basis of the disease…